Tonix Expands Tonmya Coverage by 17M Americans, Shares Jump 5%
TNXP•Tonix Pharmaceuticals secured a second commercial payer agreement for Tonmya, covering 17 million additional insured Americans and expanding total market access to 52 million lives. The stock rose 5% as investors assess the revenue boost and look ahead to a Lyme disease therapy supply expected in early 2027.
1. Payer Agreement Broadens Tonmya Coverage
Tonix announced a second commercial payer agreement for its recently launched fibromyalgia treatment Tonmya, adding access to approximately 17 million insured Americans and increasing total commercial coverage to about 52 million lives, equivalent to 29% of the U.S. commercial insurance market.
2. First New Fibromyalgia Drug in 15 Years
Launched in November 2025, Tonmya is the first FDA-approved non-opioid fibromyalgia therapy in over 15 years, designed for daily bedtime use and long-term chronic pain management with improved tolerability.
3. Lyme Disease Candidate Poised for Phase 2 Trial
The company plans a Phase 2 study of its Lyme disease antibody candidate TNX-4800, using two injections over one season to test six months of protection; drug supply is expected in early 2027 with further studies in 2028.
4. Share Movement and Investor Outlook
Shares rose 5% on the coverage expansion announcement; despite a 34% year-to-date decline, investors are increasingly bullish on potential revenue growth from the expanded payer base and upcoming pipeline catalysts.
